Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease
Bibliographic record
Abstract
Ulcerative colitis (UC) and Crohn's disease (CD) both fall under the category of inflammatory bowel diseases (IBD). UC primarily targets the large intestine and manifests through symptoms such as diarrhea, rectal bleeding, abdominal pain, a constant urge for bowel movements, and tenesmus (a sensation of needing to defecate even when the bowels are empty). CD, on the other hand, can impact any part of the gastrointestinal tract, although it often affects the ileum and colon. CD patients typically experience symptoms like abdominal pain, weight loss, and diarrhea. In cases where the disease proves severe or unresponsive to conventional therapies, such as corticosteroids, healthcare professionals may explore the potential benefits of employing biologic agents and small molecule treatments as alternative therapeutic strategies. Biologic agents, also known as biologic therapies, are a category of treatments, typically proteins or antibodies, designed to target specific components of the immune system involved in the inflammatory process of IBD. They are used to modulate the immune response and reduce inflammation in the gut. Two notable biologic therapies, ustekinumab and vedolizumab, have gained approval for the treatment of both UC and CD. Their efficacy and ability to maintain a positive response have been substantiated through various placebo-controlled trials, including GEMINI 1 (NCT00783718), UNITI 1 (NCT01369329), UNITI 2 (NCT01369342), and UNIFI (NCT02407236). Clinical remission is a critical outcome measure in assessing the effectiveness of treatments. It refers to a state in which the patient experiences a significant reduction or complete absence of symptoms related to the disease. In the case of IBD, it means the patient is no longer experiencing symptoms like abdominal pain, diarrhea, rectal bleeding, or the constant urge for bowel movements. It has been observed within these trials that patients who have previously used biologics have lower rates of clinical and endoscopic response compared to biologic-naïve patients. This 'previous use' includes those patients who did not have symptomatic improvement but also encompasses those who may have had adverse events to prior therapy. This is what we refer to as biologic intolerance. The primary objective of this study is to assess whether IBD patients with prior biologic intolerance have similar achievement of clinical remission and response to ustekinumab and vedolizumab as those who have had a prior failure of one biologic treatment. Patient-level data from GEMINI 1 and UNIFI is being requested from Vivli, while patient-level data from UNITI 1 and UNITI 2 is being requested from the YODA Project. This research will provide valuable insights into the potential of these biologic agents to induce clinical remission, even in patients with a history of biologic intolerance.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".